US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time. The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy ...
GSK announces AREXVY, its respiratory syncytial virus (RSV) …
WEBAug 17, 2023 · GSK plc (LSE/NYSE: GSK) today announced that AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) is now available in the US at all major retail pharmacies.
GSK’s RSV vaccine, AREXVY, accepted under Priority Review in US …
WEBFeb 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under Priority Review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.
AREXVY | FDA - U.S. Food and Drug Administration
WEBJun 2, 2023 · Approval History, Letters, Reviews, and Related Documents - AREXVY. For active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in ...
GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for ...
WEBAug 4, 2023 · GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults approved in Canada. Canadians aged 60 years and older can now better protect themselves against RSV disease. Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine efficacy of …
RSV Vaccine | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBAREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older. Important Safety Information. You should not receive AREXVY if …
YOU ARE ABOUT TO LEAVE A GSK WEBSITE - AREXVY
WEBAREXVY is an FDA-approved vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in people 60 years of age and older. Important Safety Information. You should not receive AREXVY if …
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
WEBJun 21, 2023 · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy (respiratory syncytial virus vaccine, adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus …
AREXVY | GSK Canada
WEBGSK plc. Registered in England and Wales No. 3888792. GlaxoSmithKline Inc. 100 Milverton Drive, Suite 800, Mississauga, ON L5R 4H1. > GSK Modern Slavery Act Statement 2023 (PDF - 154.2KB) GSK websites. GSK Global website. Market website selector. Global Behind the science magazine.
Skip to content